OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	303
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	242
In silico prediction of post-translational modifications in therapeutic antibodies	150
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	126
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	122
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	98
Correction	89
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	87
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	78
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	71
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	69
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	68
Correction	67
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	66
An antibody developability triaging pipeline exploiting protein language models	63
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	55
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	54
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	53
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	50
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	50
Correction	47
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	45
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	43
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	40
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	40

Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	39
Predicting antibody binders and generating synthetic antibodies using deep learning	39
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	39
Impact of IgG subclass on monoclonal antibody developability	38
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	37
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	36
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	35
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	35
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	33